CompanySRRKNasdaqCambridge, MA

Scholar Rock, Inc.

Scholar Rock develops monoclonal antibodies targeting myostatin to treat muscle atrophy in rare neuromuscular diseases.

SEC EDGAR ClinicalTrials.gov scholarrock.com

8-KSep 15Latest SEC filing, period to Sep 15

Aug 6Latest story

August 2026

Scholar Rock updates apitegromab BLA progress, starts FSHD Phase 2 trial

Aug 6Quarterly updateapitegromab Scholar Rock, Inc.

Scholar Rock refiles at-the-market offering for up to $200 million

Aug 6FinancingScholar Rock, Inc.